TMS-010

TMS-010 is an investigational small molecule therapeutic currently in preclinical development by TMS Co., Ltd. for the treatment of spinal cord injury (SCI). The drug is designed to protect the blood-spinal cord barrier (BBSCB), a specialized physiological barrier that, when compromised following traumatic injury, allows for the influx of inflammatory cells and neurotoxic substances into the spinal cord parenchyma. By maintaining BBSCB integrity, TMS-010 aims to reduce secondary injury processes such as edema and inflammation, which can exacerbate neurological deficits and functional loss. While the specific molecular target has not been publicly disclosed, TMS-010 is part of a pipeline focused on SMTP (Stachybotrys microspora triprenyl phenol) derivatives and soluble epoxide hydrolase (sEH) inhibitors, suggesting a potential relationship to these classes of compounds.